5:17 PM
 | 
Mar 24, 2014
 |  BC Extra  |  Clinical News

Gilead to present data for Sovaldi/GS-5816 combo

In an abstract released ahead of an upcoming liver meeting, Gilead Sciences Inc. (NASDAQ:GILD) said once-daily HCV drug Sovaldi sofosbuvir plus GS-5816 for 12...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >